Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Policy and Pricing

Policy and Pricing

Evaluate

Thumbnail
March 21, 2023

Mereo’s regulatory boost means little without a partner

Thumbnail
March 16, 2023

Biologics look set to lose US drug price negotiation loophole

Article image
Vantage logo
March 10, 2023

Polivy adcom: no overall survival, no problem

A US adcom surprisingly backs Polivy’s front-line use, and blockbuster sales could follow.

Article image
Vantage logo
March 01, 2023

Lilly bows to the inevitable on insulin price cuts

Article image
Vantage logo
February 22, 2023

US deal watchdog's bark could be worse than its bite

Chills in the biopharma M&A market are frequently blamed on the FTC. But is the agency really stopping deals from happening?  

Article image
Vantage logo
February 09, 2023

Biopharma and Medtech Review 2022

Article image
Vantage logo
January 26, 2023

US regulator stays firm on knockbacks

Article image
Vantage logo
January 18, 2023

A year of two halves for US approvals

FDA green lights picked up in the second half, but for the really impressive number look at year-five sales.

Article image
Vantage logo
December 30, 2022

Regulatory developments over the Christmas period

The FDA and Biogen come in for fierce Congressional criticism, and a handful of new cancer drugs are approved in Japan.

Article image
Vantage logo
December 06, 2022

Illumina loses its grip

The sequencing giant’s acquisition of Grail is heading for the rocks.

Article image
Vantage logo
November 23, 2022

An expensive new haemophilia gene therapy hits the US

The approval is good for CSL, and better for Uniqure.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up